Component
SAC oral bioavailability in rat mouse and dog pharmacokinetic comparisons
SAC oral bioavailability in rat mouse and dog pharmacokinetic comparisons. Interpret through the linked study species, preparation, exposure and measured endpoint.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Reported SAC oral bioavailability was 98.2% in rats, 103.0% in mice, and 87.2% in dogs.
Experimental context and source evidence
- evidence_access
- Primary indexed abstract reviewed; full methods, exact concentrations or species-specific attribution remain unextracted unless explicitly stated in the abstract or separately verified publisher text.
- experimental_model
- Species-separated pharmacokinetic estimates; original accessible abstract.
- interpretation_status
- Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
- limitations
- Not human values; estimate above 100% is variability, not additional dose. Not allicin pharmacokinetics.
- plain_language
- Reported SAC oral bioavailability was 98.2% in rats, 103.0% in mice, and 87.2% in dogs.
- primary_references
- Pharmacokinetics of the garlic compound S-allylcysteine. | 1994 | DOI 10.1055/s-2006-959461 | PMID 8073085 | https://pubmed.ncbi.nlm.nih.gov/8073085/ | https://doi.org/10.1055/s-2006-959461
- source_locator
- Reviewed reference lines 35-35; exact primary location described in quoted passage where extracted.
Allicin: detailed mechanisms of action (reviewed 5 October 2026) · lines 35–35
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Species-separated pharmacokinetic estimates; original accessible abstract. · Recorded from source · Recorded from source
**SAC pharmacokinetics are species-specific.** The frequently quoted high oral SAC bioavailability came from rats, mice, and dogs: 98.2%, 103.0%, and 87.2%, respectively, in the cited experiment. An estimate above 100% reflects the pharmacokinetic comparison and experimental variability, not creation of additional dose. These values are not measured human allicin bioavailability. [Nagae 1994](https://pubmed.ncbi.nlm.nih.gov/8073085/)
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.